Lack of in vitro synergy of clinically used antibodies specific for ICAM-1 and LFA-1

Recent evidence indicates that thrombolysis may be an effective therapy for the treatment of acute ischemic stroke. However, the reperfusion of ischemic brain comes with a price. In clinical trials, patients treated with thrombolytic therapy have shown a 6% rate of intracerebral hemorrhage, which was balanced against a 30% improvement in functional outcome over controls. Destruction of the microvasculature and extension of the infarct area occur after cerebral reperfusion. We have reviewed the existing data indicating that an inflammatory response occurring after the reestablishment of circulation has a causative role in this reperfusion injury. The recruitment of neutrophils to the area of ischemia, the first step to inflammation, involves the coordinated appearance of multiple proteins. Intercellular adhesion molecule-1 and integrins are adhesion molecules that are up-regulated in endothelial cells and leukocytes. Tumor necrosis factor-alpha, interleukin-1, and platelet-activating factor also participate in leukocyte accumulation and subsequent activation. Therapies that interfere with the functions of these factors have shown promise in reducing reperfusion injury and infarct extension in the experimental setting. They may prove to be useful adjuncts to thrombolytic therapy in the treatment of acute ischemic stroke.

show abstract

Reperfusion Injury after Focal Cerebral Ischemia: The Role of Inflammation and the Therapeutic Horizon

Jean¹,

Spellman²,

Nussbaum³

et al. 1998

Neurosurgery

125

148

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Lack of in vitro synergy of clinically used antibodies specific for ICAM-1 and LFA-1

Cited by 4 publications

References 5 publications

Leukocyte adhesion molecules in transplantation11In collaboration with The American Physiological Society, Thomas E. Andreoli, MD, Editor

Leukocyte adhesion molecules in transplantation11In collaboration with The American Physiological Society, Thomas E. Andreoli, MD, Editor

Reperfusion Injury after Focal Cerebral Ischemia: The Role Inflammation and the The rapeutic Horizon

Reperfusion Injury after Focal Cerebral Ischemia: The Role of Inflammation and the Therapeutic Horizon

Contact Info

Product

Resources

About